Therapy for anogenital verrucae in preadolescent children with topical and systemic treatment.
Administration, Topical
Antineoplastic Agents
/ therapeutic use
Antioxidants
/ therapeutic use
Catechin
/ therapeutic use
Child
Child, Preschool
Combined Modality Therapy
Condylomata Acuminata
/ drug therapy
Dermatologic Agents
/ administration & dosage
Female
Humans
Imiquimod
/ therapeutic use
Infant
Male
Retrospective Studies
Treatment Outcome
anogenital warts
children
condyloma acuminata
imiquimod
preadolescent
sinecatechins
systemic treatment
topical treatment
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
15
6
2019
medline:
29
2
2020
entrez:
15
6
2019
Statut:
ppublish
Résumé
Anogenital verrucae (AV) are benign, human papillomavirus (HPV)-induced tumors of the anogenital skin and mucosa. Medical therapy for AV in preadolescents has not been well studied. We explore the efficacy and safety profile of sinecatechins 15% ointment and imiquimod 5% cream in the treatment of AV, alone and in combination therapy with other commonly used medications. A single-institution, retrospective review of children under 12 years of age with AV treated with imiquimod 5% cream and sinecatechins 15% ointment was performed. Demographic data, side effects, and outcomes of therapy were recorded for each patient, and overall efficacy was determined. A total of 37 patients met inclusion criteria. Responses were seen in 8 out of 9 patients treated with sinecatechins 15% ointment (5 full, 3 partial, and 1 no response) and 9 out of 17 patients treated with imiquimod 5% cream (4 full, 5 partial, and 8 no response). Combination therapy with one or more of the following treatments (podophyllin, cimetidine, candida antigen injection, and HPV vaccine) were evaluated, but no combination was objectively superior to the others. No significant difference was found in overall efficacy between sinecatechins and imiquimod. Side effects were mild and limited to irritation and erythema. Both imiquimod 5% cream and sinecatechins 15% ointment are moderately effective in the treatment of AV in preadolescent children, with a trend toward greater effectiveness of sinecatechins. Combination therapy with other treatments did not significantly increase the effectiveness of topical therapies. Each modality has a tolerable side effect profile with a low risk of serious complications.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Anogenital verrucae (AV) are benign, human papillomavirus (HPV)-induced tumors of the anogenital skin and mucosa. Medical therapy for AV in preadolescents has not been well studied. We explore the efficacy and safety profile of sinecatechins 15% ointment and imiquimod 5% cream in the treatment of AV, alone and in combination therapy with other commonly used medications.
METHODS
METHODS
A single-institution, retrospective review of children under 12 years of age with AV treated with imiquimod 5% cream and sinecatechins 15% ointment was performed. Demographic data, side effects, and outcomes of therapy were recorded for each patient, and overall efficacy was determined.
RESULTS
RESULTS
A total of 37 patients met inclusion criteria. Responses were seen in 8 out of 9 patients treated with sinecatechins 15% ointment (5 full, 3 partial, and 1 no response) and 9 out of 17 patients treated with imiquimod 5% cream (4 full, 5 partial, and 8 no response). Combination therapy with one or more of the following treatments (podophyllin, cimetidine, candida antigen injection, and HPV vaccine) were evaluated, but no combination was objectively superior to the others. No significant difference was found in overall efficacy between sinecatechins and imiquimod. Side effects were mild and limited to irritation and erythema.
CONCLUSIONS
CONCLUSIONS
Both imiquimod 5% cream and sinecatechins 15% ointment are moderately effective in the treatment of AV in preadolescent children, with a trend toward greater effectiveness of sinecatechins. Combination therapy with other treatments did not significantly increase the effectiveness of topical therapies. Each modality has a tolerable side effect profile with a low risk of serious complications.
Substances chimiques
Antineoplastic Agents
0
Antioxidants
0
Dermatologic Agents
0
Catechin
8R1V1STN48
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-627Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Costa-Silva M, Fernandes I, Rodrigues AG, Lisboa C. Anogenital warts in pediatric population. An Bras Dermatol. 2017;92(5):675-681.
Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: A review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis. 2015; 61( Suppl 8): S849-S855.
Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2013;27(3):e263-e270.
Longstaff E, von Krogh G. Condyloma eradication: self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations-an integrated safety assessment. Regul Toxicol Pharmacol. 2001;33(2):117-137.
Ward JW, Clifford WS, Monaco AR, Bickerstaff HJ. Fatal systemic poisoning following podophyllin treatment of condyloma acuminatum. South Med J. 1954;47(12):1204-1206.
Godoy-Gijon E, Fraile-Alonso MC, Alonso-Vicente C, Rojo-Rello S. Treatment of pediatric anogenital condyloma acuminata with sinecatechins ointment. Dermatol Ther. 2017;30(6):e12562.
Rob F, Juzlova K, Secnikova Z, Jirakova A, Hercogova J. Successful Treatment with 10% Sinecatechins Ointment for Recurrent Anogenital Warts in an Eleven-Year-Old Child. Pediatr Infect Dis J. 2017;36(2):235-236.
Majewski S, Pniewski T, Malejczyk M, Jablonska S. Imiquimod is highly effective for extensive, hyperproliferative condyloma in children. Pediatr Dermatol. 2003;20(5):440-442.
Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J. 2004;10(1):4.
U.S. Food and Drug Administration 2007. Drug Approval Package. Veregen NDA #021902. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000TOC.cfm Accessed April 13, 2019.
Deeb M, Levy R, Pope E, Lara-Corrales I. Sinecatechins ointment for the treatment of warts in children. Pediatr Dermatol. 2019;36(1):121-124.
Leclair E, Black A, Fleming N. Imiquimod 5% cream treatment for rapidly progressive genital condyloma in a 3-year-old girl. J Pediatr Adolesc Gynecol. 2012;25(6):e119-e121.
Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol. 2007;21(10):1404-1412.
Tatti S, Stockfleth E, Beutner KR, et al. Polyphenon E: a new treatment for external anogenital warts. Br J Dermatol. 2010;162(1):176-184.
Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42(4):789-794.
Arican O, Guneri F, Bilgic K, Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol. 2004;31(8):627-631.